JP2021515010A5 - - Google Patents

Info

Publication number
JP2021515010A5
JP2021515010A5 JP2020545666A JP2020545666A JP2021515010A5 JP 2021515010 A5 JP2021515010 A5 JP 2021515010A5 JP 2020545666 A JP2020545666 A JP 2020545666A JP 2020545666 A JP2020545666 A JP 2020545666A JP 2021515010 A5 JP2021515010 A5 JP 2021515010A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkenyl
heterocyclyl
heteroaryl
Prior art date
Application number
JP2020545666A
Other languages
English (en)
Japanese (ja)
Other versions
JP7348906B2 (ja
JP2021515010A (ja
JPWO2019168999A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019854 external-priority patent/WO2019168999A1/en
Publication of JP2021515010A publication Critical patent/JP2021515010A/ja
Publication of JP2021515010A5 publication Critical patent/JP2021515010A5/ja
Publication of JPWO2019168999A5 publication Critical patent/JPWO2019168999A5/ja
Application granted granted Critical
Publication of JP7348906B2 publication Critical patent/JP7348906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020545666A 2018-02-28 2019-02-27 フェロトーシス誘導活性を有する化合物およびそれらの使用方法 Active JP7348906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636614P 2018-02-28 2018-02-28
US62/636,614 2018-02-28
PCT/US2019/019854 WO2019168999A1 (en) 2018-02-28 2019-02-27 Compounds with ferroptosis inducing activity and methods of their use

Publications (4)

Publication Number Publication Date
JP2021515010A JP2021515010A (ja) 2021-06-17
JP2021515010A5 true JP2021515010A5 (https=) 2022-06-22
JPWO2019168999A5 JPWO2019168999A5 (https=) 2022-06-22
JP7348906B2 JP7348906B2 (ja) 2023-09-21

Family

ID=65729467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545666A Active JP7348906B2 (ja) 2018-02-28 2019-02-27 フェロトーシス誘導活性を有する化合物およびそれらの使用方法

Country Status (16)

Country Link
US (2) US11098040B2 (https=)
EP (1) EP3759075B1 (https=)
JP (1) JP7348906B2 (https=)
KR (1) KR20200135961A (https=)
CN (1) CN112041301A (https=)
AR (2) AR114417A1 (https=)
AU (1) AU2019229256A1 (https=)
BR (1) BR112020017561A2 (https=)
CA (1) CA3092143A1 (https=)
EA (1) EA202091846A1 (https=)
ES (1) ES3038012T3 (https=)
IL (1) IL276788A (https=)
MX (2) MX2020008906A (https=)
SG (1) SG11202008230PA (https=)
TW (1) TW202000663A (https=)
WO (1) WO2019168999A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
MX2021010173A (es) * 2019-02-27 2021-12-10 Ferro Therapeutics Inc Compuestos con actividad inductora de ferroptosis y métodos de uso.
US20220227765A1 (en) * 2019-08-28 2022-07-21 Ferro Therapeutics, Inc. Pyrido-indole analogues as gpx4 inhibitors
CN110511253B (zh) * 2019-09-04 2023-10-13 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法
CN110627786B (zh) * 2019-10-29 2020-11-24 株洲千金药业股份有限公司 一种他达拉非中间体的制备方法
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US11998534B2 (en) * 2020-02-12 2024-06-04 Eubulus Biotherapeutics Inc. GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
CN115243719B (zh) * 2020-03-06 2024-09-13 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用
TW202227399A (zh) * 2020-08-26 2022-07-16 美商費洛醫療公司 化合物及使用方法
AU2021391453A1 (en) * 2020-12-04 2023-07-13 Eubulus Biotherapeutics Inc. Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications
KR20220139813A (ko) * 2021-04-08 2022-10-17 서울대학교산학협력단 암 환자의 예후 예측용 바이오마커 및 이의 용도
CN113336748B (zh) * 2021-04-12 2022-03-25 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024015637A1 (en) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
WO2024039860A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024123412A1 (en) * 2022-12-09 2024-06-13 The University Of Toledo Ferroptosis inducers to treat cancer
CN118994147B (zh) * 2024-07-18 2026-01-02 中国海洋大学 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用
CN120923499A (zh) * 2025-08-08 2025-11-11 兰州大学 一种铁死亡激动剂、缺氧响应型纳米共递送系统及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
WO2001094347A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
MXPA03004023A (es) 2000-11-08 2004-02-12 Lilly Icos Llc Compuestos quimicos.
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
EP1914235A1 (en) * 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
WO2011063223A1 (en) 2009-11-20 2011-05-26 Southern Research Institute TETRAHYDRO-β-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF
WO2014011973A2 (en) 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
WO2015051149A1 (en) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
EP3094332B1 (en) 2014-01-15 2018-09-12 The Trustees of Columbia University in the City of New York Carbonyl erastin analogs and their use
CN107530303A (zh) 2014-12-16 2018-01-02 Adt制药有限责任公司 Ras‑抑制性茚基乙酰胺化合物、组合物和用途
JP6974178B2 (ja) 2015-05-29 2021-12-01 メモリアル スローン ケタリング キャンサー センター フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
US20190008961A1 (en) * 2016-01-07 2019-01-10 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells
BR112018013730B1 (pt) 2016-01-08 2022-06-28 Championx Usa Inc. Método para intensificar a produção e/ou o transporte de óleo bruto
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
WO2018218087A1 (en) 2017-05-24 2018-11-29 K-Gen, Inc. Methods of cancer treatment
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
WO2019106434A1 (en) 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
CN109796424A (zh) 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用
MX2021010173A (es) 2019-02-27 2021-12-10 Ferro Therapeutics Inc Compuestos con actividad inductora de ferroptosis y métodos de uso.

Similar Documents

Publication Publication Date Title
JP2021515010A5 (https=)
AU2020394767B2 (en) Spiro compound serving as ERK inhibitor, and application thereof
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
JPWO2019168999A5 (https=)
IL275762B2 (en) History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
RU2009105826A (ru) 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ
RU2013156074A (ru) Диазакарбазолы и способы применения
KR20180050742A (ko) 아레나비리다에 및 코로나비리다에 바이러스 감염의 치료 방법
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
KR101982951B1 (ko) 신규한 유형의 시티딘 유도체 및 그의 용도
RU2007110629A (ru) Ингибиторы днк-пк
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
NZ608584A (en) Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
JP2017510660A5 (https=)
TW200621759A (en) Novel aminopyridine derivatives having aurora A selective inhibitory action
WO2007132228A1 (en) Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder
RU2014153672A (ru) Новые каберголиновые производные
RU2013136895A (ru) Новое бициклическое соединение или его соль
JP2015502371A5 (https=)
WO2008056264A3 (en) Novel nucleotide analogues as percursor molecules for antivirals
ATE67193T1 (de) 6-phenyl-pyridazin-verbindungen.
UY28688A1 (es) Derivados de amida
JPWO2020176757A5 (https=)